TPTX

TorreyPines's pain drug meets study endpoints - 12/02 - 10:44 AM ET

TPTX: Ph II Trial of NGX267 to Treat Xerostomia Meets Primary Endpoint - 12/02 - 08:57 AM ET

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia - 12/02 - 08:30 AM ET

TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects - 12/01 - 08:30 AM ET

TorreyPines licenses Posiphen, bisnorcymcerine and phenserine to QR Pharma - 11/20 - 03:45 AM ET

TorreyPines Therapeutics Inc enters licensing agreement with QR Pharma - 11/19 - 08:05 AM ET

TPTX: Licensing Agreement w/QR Pharma - 11/18 - 08:56 AM ET

TorreyPines Therapeutics Licenses Posiphen(TM), Bisnorcymcerine and Phenserine to QR Pharma - 11/18 - 08:30 AM ET

TorreyPines Therapeutics names new CEO - 11/13 - 10:29 AM ET

BRIEF-TorreyPines Therapeutics names CEO - 11/12 - 11:53 PM ET

Graham Named CEO Of TorreyPines Therapeutics - 11/12 - 09:58 PM ET

TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors - 11/12 - 04:15 PM ET

BRIEF-TorreyPines Therapeutics reports Q3 results - 11/12 - 11:34 AM ET

TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments - 11/12 - 08:30 AM ET

TorreyPines sells Alzheimer's disease genetics program to Eisai - 11/11 - 11:22 AM ET

BRIEF-TorreyPines sells Alzheimer's disease genetics program to Eisai - 11/10 - 08:54 AM ET

TorreyPines Therapeutics initiates dosing in Phase I pain trial - 10/21 - 09:15 AM ET

TPTX: Begins Dosing in Ph I Trial of NGX426 - 10/20 - 09:32 AM ET

TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel - 10/20 - 08:30 AM ET

CalciMedica exercises option to acquire intellectual property from TorreyPines - 10/14 - 05:52 AM ET

Page 1 of 4     1  2   3   4      Previous  |  Next

<< Back to Stock Index